Demant A/S (WILLF)
| Market Cap | 7.87B +5.0% |
| Revenue (ttm) | 3.61B +2.5% |
| Net Income | 242.89M -35.3% |
| EPS | 1.15 -33.5% |
| Shares Out | n/a |
| PE Ratio | 32.40 |
| Forward PE | 17.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 366 |
| Open | 37.20 |
| Previous Close | 35.58 |
| Day's Range | 37.20 - 37.20 |
| 52-Week Range | 28.08 - 43.78 |
| Beta | 0.72 |
| RSI | 56.62 |
| Earnings Date | Aug 11, 2026 |
About Demant
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark. [Read more]
Financial Performance
In 2025, Demant's revenue was 22.97 billion, an increase of 2.46% compared to the previous year's 22.42 billion. Earnings were 1.55 billion, a decrease of -35.27%.
Financial numbers in DKK Financial StatementsNews
Demant Earnings Call Transcript: Q1 2026
Strong Q1 performance with 6% organic and 10% acquisitive growth, led by Oticon Zeal’s successful launch and KIND integration. Guidance maintained, with momentum likely to push results toward the upper end of the range.
Demant Reports Strong Q1 Revenue Growth
(RTTNews) - Demant A/S (WILYY) on Tuesday reported an interim update with revenue increasing from last year, supported by strong performance in its Hearing Aids business.
Demant price target raised to DKK 210 from DKK 207 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Demant (WILYY) to DKK 210 from DKK 207 and keeps an Equal Weight rating on the shares.
Demant upgraded to Buy from Hold at Jefferies
Jefferies upgraded Demant (WILYY) to Buy from Hold with a price target of DKK 245, down from DKK 255. The firm sees share upside in 2026 from the company’s easy
Demant upgraded to Buy from Hold at Nordea
Nordea analyst Martin Brenoe upgraded Demant (WILYY) to Buy from Hold with a DKK 230 price target
Demant price target lowered to DKK 235 from DKK 290 at Citi
Citi lowered the firm’s price target on Demant (WILYY) to DKK 235 from DKK 290 and keeps a Buy rating on the shares.
Demant price target lowered to DKK 211 from DKK 242 at Deutsche Bank
Deutsche Bank analyst Falko Friedrichs lowered the firm’s price target on Demant (WILYY) to DKK 211 from DKK 242 and keeps a Hold rating on the shares. Published first on
Demant downgraded to Neutral from Outperform at BNP Paribas
BNP Paribas downgraded Demant (WILYY) to Neutral from Outperform with a DKK 200 price target
Demant price target lowered to DKK 207 from DKK 221 at Morgan Stanley
Morgan Stanley analyst Aisyah Noor lowered the firm’s price target on Demant (WILYY) to DKK 207 from DKK 221 and keeps an Equal Weight rating on the shares. Published first
Demant price target lowered to DKK 250 from DKK 288 at JPMorgan
JPMorgan lowered the firm’s price target on Demant (WILYY) to DKK 250 from DKK 288 and keeps an Overweight rating on the shares.
Demant Earnings Call Transcript: Q4 2025
Reported 2% organic growth for 2025, with strong Q4 performance in Hearing Care and Diagnostics, but margin pressure from ASP and mix. 2026 guidance targets 3%-6% organic growth, DKK 4.1-4.5bn EBIT, and cost savings, with Zeal rollout and KIND acquisition as key drivers.
Demant price target lowered to DKK 288 from DKK 291 at JPMorgan
JPMorgan analyst David Adlington lowered the firm’s price target on Demant (WILYY) to DKK 288 from DKK 291 and keeps an Overweight rating on the shares.
Demant downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Demant (WILYY) to Equal Weight from Overweight with a price target of DKK 221, down from DKK 250. The firm says macro headwinds continue to present earnings
Demant initiated with a Sector Perform at RBC Capital
RBC Capital initiated coverage of Demant (WILYY) with a Sector Perform rating and DKK 250 price target The firm sees limited opportunity for the company to gain organic revenue share
Demant price target lowered to DKK 250 from DKK 267 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Demant (WILYY) to DKK 250 from DKK 267 and keeps an Overweight rating on the shares.
Demant Earnings Call Transcript: Q3 2025
Q3 results landed at the low end of expectations, with 3% organic growth and margin pressure from negative ASP and mix effects. Market share gains were achieved in hearing aids, and the Oticon Seal launch drew strong interest. 2025 guidance remains, but at the lower end of the range.
Demant price target raised to DKK 291 from DKK 274 at JPMorgan
JPMorgan raised the firm’s price target on Demant (WILYY) to DKK 291 from DKK 274 and keeps an Overweight rating on the shares.
Demant Earnings Call Transcript: Q2 2025
Flat organic growth and margin contraction in H1 2025 were driven by weak market conditions, unfavorable mix, and FX headwinds. EBIT guidance and market growth expectations were revised down, while strong cash flow and the KIND Group acquisition marked key developments.
Demant upgraded to Equal Weight from Underweight at Barclays
Barclays upgraded Demant (WILYY) to Equal Weight from Underweight with a price target of DKK 285, up from DKK 220. The firm prefers Demant in wholesale given its “more achievable”
Demant upgraded to Outperform from Market Perform at Bernstein
Bernstein upgraded Demant (WILYY) to Outperform from Market Perform with a price target of DKK 338, up from DKK 249. The firm now sees growth tailwinds for the company that
Demant upgraded to Outperform from Neutral at BNP Paribas Exane
BNP Paribas Exane analyst Hugo Solvet upgraded Demant (WILYY) to Outperform from Neutral with a DKK 312 price target The company’s upcoming product launch should end the earnings downgrade cycle,
Demant Transcript: M&A Announcement
The acquisition of Kind Group for EUR 700 million expands the company's presence in Germany, creating one of the largest retail footprints in the market. Synergies are expected to drive profitability, with full benefits realized by 2028, and the deal is projected to be earnings accretive from year one.
Demant Transcript: M&A Announcement (Media)
A €700 million acquisition of a leading German hearing care retailer will expand the buyer's global clinic network, strengthen its market position, and is expected to add €300 million in revenue by 2026. Integration will be gradual, with no immediate layoffs planned.
Demant upgraded to Buy from Hold at Kepler Cheuvreux
Kepler Cheuvreux upgraded Demant (WILYY) to Buy from Hold with a price target of DKK 315, up from DKK 240. The firm expects the company’s tailwinds to outweigh headwinds in
Demant upgraded to Buy from Neutral at Citi
Citi analyst Giang Nguyen upgraded Demant (WILYY) to Buy from Neutral with a price target of DKK 335, up from DKK 315. The firm is now more constructive on the